Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 1/20 | 0.50 |
| ▸ | RECQL | P46063 | 1/20 | 0.48 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.48 |
| ▸ | USP2 | O75604 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | GPR119 | Q8TDV5 | 8/20 | 0.46 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.46 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | THRB | P10828 | 1/20 | 0.44 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.44 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.44 |
| ▸ | PTPN6 | P29350 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31286764 | 0.92 | HPGD (0.44) | HPGDRECQLEPHX1USP2SMN1; SMN2 | |
| SCHEMBL3142012 | 0.91 | EPHX1 (0.49) | HPGDRECQLEPHX1USP2SMN1; SMN2 | |
| SCHEMBL8366940 | 0.91 | PRMT5 (0.47) | HPGDRECQLEPHX1USP2SMN1; SMN2 | |
| SCHEMBL21063465 | 0.91 | PRMT5 (0.47) | HPGDRECQLEPHX1USP2SMN1; SMN2 | |
| SCHEMBL26893668 | 0.91 | PRMT5 (0.47) | HPGDRECQLEPHX1USP2SMN1; SMN2 | |
| SCHEMBL26466004 | 0.88 | HPGD (0.46) | HPGDRECQLEPHX1USP2SMN1; SMN2 | |
| SCHEMBL18354244 | 0.88 | HPGD (0.46) | HPGDRECQLEPHX1USP2SMN1; SMN2 | |
| SCHEMBL6319049 | 0.88 | HPGD (0.46) | HPGDRECQLEPHX1USP2SMN1; SMN2 | |
| SCHEMBL17888533 | 0.88 | HPGD (0.37) | HPGDRECQLEPHX1GPR119PRMT5 | |
| SCHEMBL610184 | 0.88 | HPGD (0.50) | HPGDRECQLEPHX1USP2SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023141570-A9 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF KRAS | ARVINAS OPERATIONS, INC. (US) | 2024-06-27 | — | — | WO | disclosed |
| CN-114728917-B | Oxamide derivative, preparation method and medical application thereof | 深圳信立泰药业股份有限公司 | 2023-12-08 | — | — | CN | disclosed |
| WO-2023141570-A2 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF KRAS | ARVINAS OPERATIONS, INC. (US) | 2023-07-27 | — | — | WO | disclosed |
| WO-2023141570-A2 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF KRAS | ARVINAS OPERATIONS, INC. (US) | 2023-07-27 | — | — | WO | disclosed |
| CN-114728917-A | Oxamide derivative, preparation method and medical application thereof | 深圳信立泰药业股份有限公司 | 2022-07-08 | — | — | CN | disclosed |
| WO-2021110076-A1 | OXAMIDE DERIVATIVES, PREPARATION METHOD THEREFOR AND USE THEREOF IN MEDICINE | 深圳信立泰药业股份有限公司 | 2021-06-10 | — | — | WO | disclosed |
| EP-3040329-B1 | AROMATIC COMPOUND AND USE THEREOF IN THE TREATMENT OF DISORDERS ASSOCIATED WITH BONE METABOLISM | KYOTO PHARMA IND (JP) | 2018-10-10 | — | — | EP | disclosed |
| US-10059663-B2 | Aromatic compound and use thereof | KYOTO PHARMACEUTICAL INDUSTRIES, LTD. (JP) | 2018-08-28 | — | — | US | disclosed |
| US-20160207883-A1 | NOVEL AROMATIC COMPOUND AND USE THEREOF | KYOTO PHARMACEUTICAL INDUSTRIES, LTD. (JP) | 2016-07-21 | — | — | US | disclosed |
| US-20160207883-A1 | NOVEL AROMATIC COMPOUND AND USE THEREOF | KYOTO PHARMACEUTICAL INDUSTRIES, LTD. (JP) | 2016-07-21 | — | — | US | disclosed |
| US-20160207883-A1 | NOVEL AROMATIC COMPOUND AND USE THEREOF | KYOTO PHARMACEUTICAL INDUSTRIES, LTD. (JP) | 2016-07-21 | — | — | US | disclosed |
| EP-3040329-A1 | NOVEL AROMATIC COMPOUND AND USE THEREOF | Kyoto Pharmaceutical Industries, Ltd. (JP) | 2016-07-06 | — | — | EP | disclosed |
| US-20100280024-A1 | RENIN INHIBITORS | CADILA HEALTHCARE LIMITED (IN) | 2010-11-04 | — | — | US | disclosed |
| EP-2205559-A1 | RENIN INHIBITORS | Cadila Healthcare Limited (IN) | 2010-07-14 | — | — | EP | disclosed |
| WO-2009087649-A1 | RENIN INHIBITORS | CADILA HEALTHCARE LIMITED (IN) | 2009-07-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160207883-A1 | NOVEL AROMATIC COMPOUND AND USE THEREOF | SOST, BMP2, ALPI | HPGD 2083/4885RECQL 4508/4885EPHX1 1651/4885 |
| US-20100280024-A1 | RENIN INHIBITORS | REN, ACE, AGTR1 | HPGD 599/4885RECQL 1885/4885EPHX1 702/4885 |
| US-10059663-B2 | Aromatic compound and use thereof | SOST, ALPI, FGF23 | HPGD 2043/4885RECQL 4525/4885EPHX1 1696/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.